PUBLISHED DATE : Feb 2021 | Pages : 345
| Up to $1050 off | Until Dec 2022 |
Fill out your details & get your free sample
Erectile Dysfunction Market Size, Share, Trends Analysis Report by Products (Drugs and Devices); Drugs (ROA – Oral Drugs, Topical Formulation, Penile Injections & Suppositories and Distribution - Hospital Pharmacies, Offline Retail Pharmacies, and Online Channels); Devices (Penile Implants, Vacuum Therapy Devices, Shockwave Therapy, and Others); and Geography (North America, Europe, APAC, Latin America, and the Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026
345 Pages
110 Tables
151 Charts
5 Regions
18 Countries
46 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| MARKET SIZE (REVENUE) | 4.7 BILLION (2026) |
| Base Year | 2020 |
| Forecast Year | 2021–2026 |
| Market Segments | Products (Drugs and Devices); Drugs (ROA – Oral Drugs, Topical Formulation, Penile Injections & Suppositories and Distribution - Hospital Pharmacies, Offline Retail Pharmacies, and Online Channels); Devices (Penile Implants, Vacuum Therapy Devices, Shockwave Therapy, and Others) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, Saudi Arabia, UAE, and South Africa |
The global erectile dysfunction market size will be valued at USD 4.7 billion by 2026. The APAC region is projected to grow at the highest CAGR during 2021–2026 due to the increase in the aging population and high incidence of diabetes, hypertension, and cardiovascular diseases. The global erectile dysfunction market is expected to observe a negative growth during the forecast period because of the decline in revenue from the ED therapeutics segment. The presence of several generic companies and the patent expiry of blockbuster ED drugs, including Viagra, Cialis, and Levitra, are expected to hamper ED drugs' growth. However, the overall market is expected to benefit from the steady growth observed in ED devices. The non-invasive nature and no adverse effects profile of shock wave therapy are the primary factors influencing the ED device market's growth. The increasing focus of vendors in manufacturing new innovative technologies such as vibrators and magnetic therapy for the management of ED is further boosting the ED devices market. The introduction of magnetic therapy for the treatment of ED is likely to drive the demand for ED devices. However, the outbreak of the COVID-19 pandemic and hospitals' unavailability for penile implantations hindered the ED devices market in 2020. Nevertheless, a high incidence of the disease followed by the wide availability of generic medications and advanced technological advances in ED devices are likely to boost the market during the forecast period.
This research report includes a detailed segmentation by
Erectile Dysfunction (ED) drugs occupy the major share of the ED drugs market due to physicians' high recommendations and high efficiency. The advent of topical formulations and innovations in minimal invasive penile suppositories is likely to boost the market during the forecast period. Oral drugs consist of PDE-5 inhibitors, which are considered as the first-line treatment option by physicians for the treatment of ED. However, the oral drug sub-segment is experiencing a negative CAGR due to the loss of patent protection.
ED devices are anticipated to grow at a CAGR of over 3% during the forecast period. The growth can be attributed to increased innovations in ED devices. Penile implants constitute the majority of share in the ED devices segment. Furthermore, the non-invasive nature and no adverse effects profile of shock wave therapy is a primary factor driving the ED devices market. The increasing focus of vendors in manufacturing new innovative technologies such as vibrators and magnetic therapy for the management of ED also influences the growth. The Introduction of magnetic therapy for treating the disease is also likely to boost the device market in the future. However, the COVID-19 outbreak and hospitals' unavailability for penile implantations or surgeries hampered growth in 2020.
Oral drugs are found to be more effective and safe drugs and are considered first-line therapy in the treatment of ED. Hence, these drugs account for over 94% share of the market. Innovations in oral PDE-5 inhibitors include novel oral transmucosal drug delivery through oral dispersive tablets, or oral dispersible film is expected to boost market growth during the forecast period. The high prevalence of vascular and chronic diseases such as diabetes, hypertension, psychological disorders, etc., is likely to influence segment growth.
An increase in the failure rates of oral medications for ED, which are as high as 60% in some patient populations, and increasing efficacy of injectable medication are important factors driving patients to opt for penile injections. Intracavernosal injections are considered as an alternative for oral PDE-5 inhibitors due to increasing effectiveness and sufficient erection. Penile injections are preferable for patients that are contraindicated for oral PDE-5 inhibitors or intolerable to oral medications, reliable rigidity, and rapid onset of erection. However, complications with penile injections such as priapism, failures to respond to intracavernosal or intraurethral injections, and increased efficacy of oral medications limit the growth of penile injections.
Based on device type, penile implants dominate the device market, accounting for over 49% shares, followed by VCD (vacuum constriction devices) and shockwave therapy. Penile implantations are recommended when the patient fails to respond via oral PDE-5 inhibitors or penile injections. Although penile implantations are considered the last option by physicians, their demand increases due to the high efficacy of up to 90% satisfactory erection among patients. However, malfunctioning, erosions, infections, lack of medical expertise about implantation, and the high cost of implants are expected to hamper the growth of penile implantations.
Vacuum constriction devices (VCD) accounted for over 39% of the global erectile dysfunction devices market in 2020. These devices are experiencing growth owing to their non-invasive nature and high patient satisfaction. Over 90% of the patient population experienced successful erectile function with VCD, thereby boosting the market growth. North America dominates ED devices' usage due to the high accessibility to healthcare infrastructure, high prevalence of ED disorder, and increasing chronic health disorders. Furthermore, APAC is also observed to have increased growth due to an increase in disease awareness.
Retail pharmacies account for the largest share of the global ED drugs market. Retail pharmacies are considered major centers to procure medicines. Easy access to medicines and the availability of generic ED drugs via retail pharmacies increase the market share of retail pharmacies. Hospital pharmacies constituted over 33% shares in the market. The growing awareness of erectile dysfunction and other sex-related disorders has highly increased the revenue of hospitals. Developed countries are the major contributors to hospital pharmacies as patients prefer prescribed medication for ED. However, hospital pharmacies experienced negative growth in 2020 due to the outbreak of the COVID-19 pandemic.
Online portals play a major role in delivering erectile dysfunction drugs. Ease access to medications and decreased social stigma regarding sexual dysfunctions are major factors leading to segment growth. The accessibility of online portals by pharmaceutical companies such as Pfizer, Cipla providing ED medication through CiplaMed and Viagra website increases patient treatment preference. Online portals experienced higher growth in 2020 than retail pharmacies and hospital pharmacies due to the COVID-19 pandemic, which increased the online purchase of medicines.
The increasing focus on strategic agreements and collaborations is driving the North American ED market. The region accounted for shares of around 37% of the total erectile dysfunction market share. Factors contributing to the growth include better access to erectile dysfunction prescription and generic drugs, reimbursement coverage for surgeries in ED, better healthcare infrastructure, increase in R&D innovations, high demand for ED drugs are likely to drive the market. The US is a major contributor to the North America region, accounting for over 90% of the market share. Approximately 18 million men are affected by erectile dysfunction in the US. With the increase in chronic diseases, the incidence of ED is growing. Over 50% and 51.3% of people with cardiovascular diseases and diabetes, respectively, are likely to experience erectile dysfunction.
The global ED drugs market is observed to be oligopoly in nature, wherein only a few sellers occupy the dominant market share. Pfizer, Eli Lilly and Company, Bayer, Teva Pharmaceuticals, Viatris, Dong-A-Socio Holdings, and Vivus are the key players offering oral ED drugs. Although the blockbuster oral drugs of ED lost their patent protection, the drug market is expected to witness sustainable growth due to the high availability of generic versions. Branded drugs offered by global players are introduced as generic drugs for treating ED. The competitiveness among vendors is significantly high because of the accessibility to a wide range of low-cost generic drugs and OTC topical drug formulations for treating ED. Companies whose patents expired are expected to face strong competition from vendors offering generic drugs, topical creams, and non-invasive options.
Segmentation by Products
By Drugs
By Devices
By Geography
Frequently Asked Questions
What is the market size of the erectile dysfunction market during the period 2021-2026?
The global erectile dysfunction market is expected to reach revenue of over USD 4.7 billion by 2026.
Which new ED devices are introduced for the treatment of erectile dysfunction?
Low-intensity shock wave extracorporeal therapies, tissue engineering, gene therapies, nanotechnology, stem cell therapies, and endovascular technology are some of the latest devices introduced in the market.
What are the threats faced by the existing key players in the ED industry?
Patent expiries are the major threat faced by the existing key players.
Retail pharmacies are expected to account for the highest revenue during the forecast period.
Which region to account for the highest incremental revenue during the forecast period?
The APAC region is expected to contribute the highest incremental revenue during the forecast period.
The global erectile dysfunction is expected to cross USD 4.7 billion by 2026.
The following factors are likely to contribute to the growth of the erectile dysfunction market during the forecast period:
Base Year: 2020
Forecast Year: 2021–2026
The study considers the present scenario of the erectile dysfunction market and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Prominent Vendors
Other Prominent Vendors
Products
Drugs
Devices
Geography
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusion
4.2 Base Year
4.3 Scope of The Study
4.4 Market Segments
4.4.1 Market Segmentation by Product
4.4.2 ED Drugs Market Segmentation by ROA
4.4.3 ED Drugs Market Segmentation by Distribution
4.4.4 ED Devices Market Segmentation by Product
4.4.5 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.1.1 Signs & Symptoms Of ED
7.1.2 Classification of ED
7.1.3 Etiology of ED
7.1.4 Epidemiology
7.1.5 Diagnosis & Treatment of ED
7.1.6 ED Treatment
8 Pipeline Landscape
8.1 Overview
8.2 Key Investigational Drugs/Devices
8.3 Terminated/Withdrawn Drug/Device Candidates
8.4 Key Product Profiles
8.4.1 MED3000
8.4.2 YM178
8.4.3 SST-6006
9 Marketed Product Landscape
9.1 Overview
9.2 Comparision of ED Pharmaceuticals
9.2.1 Comparison of Pharmacological Drugs For ED
9.2.2 Comparison of ED Devices
10 Market Opportunities & Trends
10.1 Emergence Of Innovative Ed Treatment Technologies
10.2 Increasing Strategic Agreements & Collaborations
10.3 Increase In E-Commerce Delivery Of ED Drugs & Devices
10.4 Advancements In ED Drug Formulations
11 Market Growth Enablers
11.1 Increasing Incidence Of Erectile Dysfunction And Other Chronic Diseases
11.2 Advancements In Erectile Dysfunction Treatment Devices
11.3 Topical Formulation As A New Treatment For Impotence
12 Market Restraints
12.1 Low Patient Compliance Toward ED Treatment
12.2 Key Patent Expiries & Availability Of Low-Cost Generics
12.3 Complications Associated With Erectile Drugs & Devices
12.4 Availability Of Alternative Treatments For ED
12.5 Threat From Counterfeit Drugs In Treating Erectile Dysfunction
13 Market Landscape
13.1 Market Overview
13.2 Market Size & Forecast
13.3 Five Forces Analysis
13.3.1 Threat of New Entrants
13.3.2 Bargaining Power of Suppliers
13.3.3 Bargaining Power of Buyers
13.3.4 Threat of Substitutes
13.3.5 Competitive Rivalry
14 Product
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
15 Drugs
15.1 Market Overview
15.1.1 COVID-19 Impact on Erectile Dysfunction Drugs Market
15.2 Market Size & Forecast
15.3 Drugs: ROA Segmentation
15.3.1 Oral Drugs: Market Size & Forecast
15.3.2 Penile Injections and Intraurethral Suppositories: Market Size & Forecast
15.3.3 Topical Formulations: Market Size & Forecast
15.4 Drugs: Distribution Channel Segmentation
15.4.1 Market Snapshot & Growth Engine
15.4.2 Retail Pharmacies: Market Size & Forecast
15.4.3 Hospital Pharmacies: Market Size & Forecast
15.4.4 Online Portals: Market Size & Forecast
15.5 Drugs: Geography Segmentation
15.5.1 Market Snapshot & Growth Engine
16 Devices
16.1 Market Overview
16.1.1 COVID-19 Impact on Erectile Dysfunction Devices Market
16.2 Market Size & Forecast
16.3 Devices: Device Type Segmentation
16.3.1 Market Snapshot & Growth Engine
16.3.2 Penile Implants: Market Size & Forecast
16.3.3 Vacuum Constriction Devices: Market Size & Forecast
16.3.4 Shock Wave Therapy Devices: Market Size & Forecast
16.3.5 Others: Market Size & Forecast
16.4 Devices: Geography Segmentation
16.4.1 Market Snapshot & Growth Engine
17 Geography
17.1 Market Snapshot & Growth Engine
17.2 Geographic Overview
18 North America
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 US: Market Size & Forecast
18.3.2 Canada: Market Size & Forecast
19 Europe
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 UK: Market Size & Forecast
19.3.2 Germany: Market Size & Forecast
19.3.3 France: Market Size & Forecast
19.3.4 Italy: Market Size & Forecast
19.3.5 Spain: Market Size & Forecast
20 APAC
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Japan: Market Size & Forecast
20.3.2 China: Market Size & Forecast
20.3.3 India: Market Size & Forecast
20.3.4 Australia: Market Size & Forecast
20.3.5 South Korea: Market Size & Forecast
21 Latin America
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Key Countries
21.3.1 Brazil: Market Size & Forecast
21.3.2 Mexico: Market Size & Forecast
21.3.3 Argentina: Market Size & Forecast
22 Middle East & Africa
22.1 Market Overview
22.2 Market Size & Forecast
22.3 Key Countries
22.3.1 Saudi Arabia: Market Size & Forecast
22.3.2 UAE: Market Size & Forecast
22.3.3 South Africa: Market Size & Forecast
23 Competitive Landscape
23.1 Competitive Overview
23.1.1 Overview of ED Drugs
23.1.2 Overview of ED Devices
23.2 Market Share Analysis
23.2.1 Bayer
23.2.2 Boston Scientific
23.2.3 Coloplast
23.2.4 Dong-A-Socio Holdings
23.2.5 Eli Lilly and Company
23.2.6 Pfizer
23.2.7 Teva Pharmaceuticals
23.2.8 Viatris
23.2.9 Vivus
24 Key Company Profiles
24.1 Eli Lilly and Company
24.1.1 Business Overview
24.1.2 Product Offerings
24.1.3 Key Strategies
24.1.4 Key Strengths
24.1.5 Key Opportunities
24.2 Vivus
24.2.1 Business Overview
24.2.2 Product Offerings
24.2.3 Key Strategies
24.2.4 Key Strengths
24.2.5 Key Opportunities
24.3 Pfizer
24.3.1 Business Overview
24.3.2 Product Offerings
24.3.3 Key Strategies
24.3.4 Key Strengths
24.3.5 Key Opportunities
24.4 Bayer
24.4.1 Business Overview
24.4.2 Product Offerings
24.4.3 Key Strategies
24.4.4 Key Strengths
24.4.5 Key Opportunities
24.5 Boston Scientific
24.5.1 Business Overview
24.5.2 Product Offerings
24.5.3 Key Strategies
24.5.4 Key Strengths
24.5.5 Key Opportunity
24.6 Coloplast
24.6.1 Business Overview
24.6.2 Product Offerings
24.6.3 Key Strategies
24.6.4 Key Strengths
24.6.5 Key Opportunities
24.7 Teva Pharmaceuticals
24.7.1 Business Overview
24.7.2 Product Offerings
24.7.3 Key Strategies
24.7.4 Key Strengths
24.7.5 Key Opportunities
24.8 Viatris
24.8.1 Business Overview
24.8.2 Product Offerings
24.8.3 Key Strategies
24.8.4 Key Strengths
24.8.5 Key Opportunity
24.9 Dong–A Socio Holdings
24.9.1 Business Overview
24.9.2 Product Offerings
24.9.3 Key Strategies
24.9.4 Key Strength
24.9.5 Key Opportunity
25 Other Prominent Vendors
25.1 Aurobindo Pharma
25.1.1 Business Overview
25.1.2 Product Offerings
25.1.3 Key Strategies
25.1.4 Key Strengths
25.1.5 Key Opportunities
25.2 Dr. Reddy’s Laboratories
25.2.1 Business Overview
25.2.2 Product Offerings
25.2.3 Key Strategies
25.2.4 Key Strengths
25.2.5 Key Opportunities
25.3 Cristalia
25.3.1 Business Overview
25.3.2 Product Offerings
25.3.3 Key Strategies
25.3.4 Key Strengths
25.3.5 Key Opportunity
25.4 Metuchen Pharmaceuticals
25.4.1 Business Overview
25.4.2 Product Offerings
25.4.3 Key Strategies
25.4.4 Key Strength
25.4.5 Key Opportunity
25.5 Menarini Group
25.5.1 Business Overview
25.5.2 Product Offerings
25.5.3 Key Strategies
25.5.4 Key Strengths
25.5.5 Key Opportunity
25.6 SK chemicals
25.6.1 Business Overview
25.6.2 Product Offerings
25.6.3 Key Strategies
25.6.4 Key Strengths
25.6.5 Key Opportunities
25.7 Seelos Therapeutics
25.7.1 Business Overview
25.7.2 Product Offerings
25.7.3 Key Strategies
25.7.4 Key Strengths
25.7.5 Key Opportunities
25.8 GlaxoSmithKline
25.8.1 Business Overview
25.8.2 Product Offerings
25.8.3 Key Strategies
25.8.4 Key Strengths
25.8.5 Key Opportunity
25.9 Sanofi
25.9.1 Business Overview
25.9.2 Product Offerings
25.9.3 Key Strategy
25.9.4 Key Strengths
25.9.5 Key Opportunities
25.10 Lupin
25.10.1 Business Overview
25.10.2 Product Offerings
25.10.3 Key Strategies
25.10.4 Key Strengths
25.10.5 Key Opportunity
25.11 Cipla
25.11.1 Business Overview
25.11.2 Product Offerings
25.11.3 Key Strategies
25.11.4 Key Strengths
25.11.5 Key Opportunities
25.12 Sandoz
25.12.1 Business Overview
25.12.2 Product Offering
25.12.3 Key Strategies
25.12.4 Key Strengths
25.12.5 Key Opportunity
25.13 Endo International
25.13.1 Business Overview
25.13.2 Product Offerings
25.13.3 Key Strategies
25.13.4 Key Strengths
25.13.5 Key Opportunities
25.14 Ferring Pharmaceuticals
25.14.1 Business Overview
25.14.2 Product Offerings
25.14.3 Key Strategies
25.14.4 Key Strengths
25.14.5 Key Opportunity
25.15 ADVANZ PHARMA
25.15.1 Business Overview
25.15.2 Product Offerings
25.15.3 Key Strategy
25.15.4 Key Strengths
25.15.5 Key Opportunities
25.16 Alembic Pharmaceuticals
25.16.1 Business Overview
25.16.2 Product Offerings
25.16.3 Key Strategies
25.16.4 Key Strength
25.16.5 Key Opportunities
25.17 Guangzhou Pharmaceutical Holdings
25.17.1 Business Overview
25.17.2 Product Offerings
25.17.3 Key Strategy
25.17.4 Key Strengths
25.17.5 Key Opportunity
25.18 iX Biopharma
25.18.1 Business Overview
25.18.2 Product Offerings
25.18.3 Key Strategy
25.18.4 Key Strengths
25.18.5 Key Opportunities
25.19 Dornier MedTech
25.19.1 Business Overview
25.19.2 Product Offerings
25.19.3 Key Strategies
25.19.4 Key Strengths
25.19.5 Key Opportunity
25.20 Zephyr Surgical Implants
25.20.1 Business Overview
25.20.2 Product Offerings
25.20.3 Key Strategies
25.20.4 Key Strengths
25.20.5 Key Opportunity
25.21 Augusta Medical Systems
25.21.1 Business Overview
25.21.2 Product Offerings
25.21.3 Key Strategy
25.21.4 Key Strength
25.21.5 Key Opportunity
25.22 Launch Medical
25.22.1 Business Overview
25.22.2 Product Offerings
25.22.3 Key Strategy
25.22.4 Key Strength
25.22.5 Key Opportunity
25.23 Bonro Medical
25.23.1 Business Overview
25.23.2 Product Offerings
25.23.3 Key Strategy
25.23.4 Key Strength
25.23.5 Key Opportunity
25.24 Owen Mumford
25.24.1 Business Overview
25.24.2 Product Offerings
25.24.3 Key Strategies
25.24.4 Key Strengths
25.24.5 Key Opportunity
25.25 Direx Group
25.25.1 Business Overview
25.25.2 Product Offerings
25.25.3 Key Strategy
25.25.4 Key Strength
25.25.5 Key Opportunity
25.26 Zimmer Medizin Systeme
25.26.1 Business Overview
25.26.2 Product Offerings
25.26.3 Key Strategies
25.26.4 Key Strengths
25.26.5 Key Opportunity
25.27 MTS Medical UG
25.27.1 Business Overview
25.27.2 Product Offerings
25.27.3 Key Strategy
25.27.4 Key Strengths
25.27.5 Key Opportunity
25.28 Medispec
25.28.1 Business Overview
25.28.2 Product Offerings
25.28.3 Key Strategies
25.28.4 Key Strengths
25.28.5 Key Opportunity
25.29 Inceler Medical
25.29.1 Business Overview
25.29.2 Product Offerings
25.29.3 Key Strategies
25.29.4 Key Strength
25.29.5 Key Opportunity
25.30 NOVAmedtek
25.30.1 Business Overview
25.30.2 Product Offerings
25.30.3 Key Strategy
25.30.4 Key Strength
25.30.5 Key Opportunity
25.31 WIKKON
25.31.1 Business Overview
25.31.2 Product Offering
25.31.3 Key Strategy
25.31.4 Key Strengths
25.31.5 Key Opportunity
25.32 Top Quality Group
25.32.1 Business Overview
25.32.2 Product Offerings
25.32.3 Key Strategy
25.32.4 Key Strengths
25.32.5 Key Opportunity
25.33 Promedon
25.33.1 Business Overview
25.33.2 Product Offerings
25.33.3 Key Strategy
25.33.4 Key Strengths
25.33.5 Key Opportunities
25.34 Timm medical technologies
25.34.1 Business Overview
25.34.2 Product Offerings
25.34.3 Key Strategy
25.34.4 Key Strength
25.34.5 Key Opportunity
25.35 Global Life Technologies
25.35.1 Business Overview
25.35.2 Product Offerings
25.35.3 Key Strategy
25.35.4 Key Strength
25.35.5 Key Opportunity
25.36 Urology Health Store
25.36.1 Business Overview
25.36.2 Product Offering
25.36.3 Key Strategy
25.36.4 Key Strength
25.36.5 Key Opportunity
25.37 Hims
25.37.1 Business Overview
25.37.2 Product Offerings
25.37.3 Key Strategy
25.37.4 Key Strength
25.37.5 Key Opportunity
26 Report Summary
26.1 Key Takeaways
26.2 Strategic Recommendations
27 Quantitative Summary
27.1 Product
27.2 Geography
27.2.1 North America: Product Segmentation
27.2.2 Europe: Product Segmentation
27.2.3 APAC: Product Segmentation
27.2.4 Latin America: Product Segmentation
27.2.5 Middle East & Africa: Product Segmentation
27.3 ED Drugs
27.3.1 ED Drugs: ROA Segmentation
27.3.2 ED Drugs: Distribution Channel Segmentation
27.3.3 ED Drugs: Geography Segmentation
27.4 ED Devices
27.4.1 ED Devices: Product Segmentation
27.4.2 ED Devices: Geography Segmentation
28 Appendix
28.1 Abbreviations
List Of Exhibits
Exhibit 1 Segmentation of Global Erectile Dysfunction Treatment Market
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 Schematic Representation of Penile Erection
Exhibit 4 Pathophysiology of Erectile Dysfunction
Exhibit 5 Signs and Symptoms of Erectile Dysfunction
Exhibit 6 ED Classification according to International Society of Impotence Research
Exhibit 7 Etiology of Erectile Dysfunction
Exhibit 8 Global Increasing Prevalence of ED 1995& 2025 (in million)
Exhibit 9 Clinical Evaluation in Patients Suffering from ED
Exhibit 10 Treatment Algorithm for ED
Exhibit 11 Impact of Emergence of Innovative ED Treatment Technologies
Exhibit 12 Impact of Increasing Strategic Agreements & Collaborations
Exhibit 13 Impact of Increasing in e-Commerce Delivery of ED Drugs & Devices
Exhibit 14 Global E-Pharmacy Revenue 2019 & 2027 (in billion)
Exhibit 15 Factors Driving the Utilization of E-pharmacy Platform among the Patient Population
Exhibit 16 Impact of Advancements in ED Drug Formulations
Exhibit 17 Impact of Increasing Incidence of Erectile Dysfunction and Other Chronic Diseases
Exhibit 18 Prevalence Rate of ED in Different Geographic Regions (%)
Exhibit 19 Increasing Global Erectile Dysfunction Prevalence (1995 & 2025) (million)
Exhibit 20 Prevalence of Erectile Dysfunction with Age (%)
Exhibit 21 Prevalence of Benign Prostatic Hyperplasia (BPH) in Different Geographies (%)
Exhibit 22 Increasing Prevalence of Diabetes Mellitus (2019−2045) (million)
Exhibit 23 Impact of Advancements in Erectile Dysfunction Treatment Devices
Exhibit 24 Various Non-Pharmacological Options for ED Treatment
Exhibit 25 Impact of Topical Formulations as a New Treatment for Impotence
Exhibit 26 Impact of Low Patient Compliance toward ED Treatment
Exhibit 27 Prevalence of ED in US and Spain (70−75 Years Old Men)
Exhibit 28 Percentage of Health-seeking Rate for ED (20−75 Years Old) in US & Germany
Exhibit 29 Factors Affecting Medical Help-seeking Behavior in ED Patients
Exhibit 30 Willingness to Discuss ED According to its Severity (%)
Exhibit 31 Impact of Key Patent Expiries & Availability of Low-cost Generics
Exhibit 32 Pfizer’s Viagra Revenue 2015-2019 ($ million)
Exhibit 33 Eli Lilly and Company’s Cialis (Tadalafil) Revenue in US ($ million)
Exhibit 34 Impact of Complications Associated with Erectile Drugs & Devices
Exhibit 35 Complications Associated with Alprostadil Injection
Exhibit 36 Side effects and Serious Adverse Events Associated with PDE-5 Inhibitors
Exhibit 37 Adverse Reactions Associated with Erectile Devices
Exhibit 38 Impact of Availability of Alternative Treatments for ED
Exhibit 39 Alternative Treatment Options for Erectile Dysfunction
Exhibit 40 Impact of Threat from Counterfeit Drugs in Treating Erectile Dysfunction
Exhibit 41 Factors Contributing to Large Counterfeit Version Market in Erectile Dysfunction
Exhibit 42 Factors Responsible for the Purchase of Counterfeit Version of Medicines in Erectile Dysfunction
Exhibit 43 Global Erectile Dysfunction Treatment Market 2020–2026 ($ million)
Exhibit 44 Global Erectile Dysfunction Treatment Market by Geography
Exhibit 45 Global Erectile Dysfunction Treatment Market by Product
Exhibit 46 Global Erectile Dysfunction Drugs Market by ROA
Exhibit 47 Erectile Dysfunction Devices Market by Product
Exhibit 48 Five Forces Analysis 2020
Exhibit 49 Incremental Growth by Product 2020 & 2026
Exhibit 50 Global Erectile Dysfunction Treatment Market by Product
Exhibit 51 Global Erectile Dysfunction Treatment Market by Product: Incremental Growth
Exhibit 52 Global Erectile Dysfunction Treatment Market by Product: Absolute Growth
Exhibit 53 Global ED Drugs Market 2020–2026 ($ million)
Exhibit 54 Incremental Growth by ROA 2020 & 2026
Exhibit 55 Global Erectile Dysfunction Treatment Market by ROA
Exhibit 56 Common PDE-5 Inhibitors Used in the Treatment of Erectile Dysfunction
Exhibit 57 Global Erectile Dysfunction Drugs Market by Oral Drugs 2020–2026 ($ million)
Exhibit 58 Global ED Drugs Market by Penile Injections and Intraurethral Suppositories 2020−2026 ($ million)
Exhibit 59 Companies Offering Penile Injections and Intraurethral Suppositories for Treating ED
Exhibit 60 Advantages with Topical Formulations over PDE-5 Inhibitors for the Treatment of ED
Exhibit 61 Global ED Drugs Market by Topical Formulations
Exhibit 62 Incremental Growth by Distribution Channel 2020 & 2026
Exhibit 63 Global Erectile Dysfunction Drugs Market by Distribution
Exhibit 64 Global ED Drugs Market by Retail Pharmacies 2020–2026 ($ million)
Exhibit 65 Global ED Drugs Market by Hospital Pharmacies 2020–2026 ($ million)
Exhibit 66 Global ED Drugs Market by Online Pharmacies 2020−2026 ($ million)
Exhibit 67 Incremental Growth by Geography 2020 & 2026
Exhibit 68 Global ED Devices Market 2020–2026 ($ million)
Exhibit 69 Incremental Growth by Device Type 2020 & 2026
Exhibit 70 Global Erectile Dysfunction Treatment Market by Device Type
Exhibit 71 Advantages with Penile Implantation in the Treatment of Impotence
Exhibit 72 Global ED Devices Market by Penile Implants 2020−2026 ($ million)
Exhibit 73 Advantages with Vacuum Construction Devices in Treatment of Erectile Dysfunction
Exhibit 74 Global ED Devices Market by Vacuum Constriction Devices 2020−2026 ($ million)
Exhibit 75 Benefits with Low-intensity Shock Wave Therapy for ED
Exhibit 76 Global ED Devices Market by Shock Wave Therapy 2020−2026 ($ million)
Exhibit 77 Global ED Devices Market by Others Segment 2020−2026 ($ million)
Exhibit 78 Incremental Growth by Geography 2020 & 2026
Exhibit 79 Incremental Growth by Geography 2020 & 2026
Exhibit 80 Global Erectile Dysfunction Treatment Market by Geography
Exhibit 81 Global Erectile Dysfunction Treatment Market by Geography 2020: Key Countries ($ million)
Exhibit 82 Global Erectile Dysfunction Treatment Market by Geography: Incremental Growth
Exhibit 83 Global Erectile Dysfunction Treatment Market by Geography: Absolute Growth
Exhibit 84 Erectile Dysfunction Treatment Market in North America 2020–2026 ($ million)
Exhibit 85 Incremental Growth in North America 2020 & 2026
Exhibit 86 Prevalence of ED Treatment in Accordance with Age in US
Exhibit 87 Prevalence of Co-morbidities with and without ED in US
Exhibit 88 Erectile Dysfunction Treatment Market in US 2020–2026 ($ million)
Exhibit 89 Impact of Patent Expiration on Viagra and Cialis Revenue Rates 2017−2019 (in million)
Exhibit 90 Penile Implantation According to Region
Exhibit 91 Percent Probability of ED with Co-morbid Conditions in Men aged 40-49
Exhibit 92 Erectile Dysfunction Treatment Market in Canada 2020–2026 ($ million)
Exhibit 93 Erectile Dysfunction Treatment Market in Europe 2020–2026 ($ million)
Exhibit 94 Incremental Growth in Europe 2020 & 2026
Exhibit 95 Erectile Dysfunction Treatment Market in UK 2020–2026 ($ million)
Exhibit 96 Percentage of Prevalence of Erectile Dysfunction in Germany with Age (30–80 years)
Exhibit 97 Source of Potency of ED Drugs in Germany
Exhibit 98 Erectile Dysfunction Treatment Market in Germany 2020–2026 ($ million)
Exhibit 99 Erectile Dysfunction Treatment Market in France 2020–2026 ($ million)
Exhibit 100 Erectile Dysfunction Treatment Market in Italy 2020–2026 ($ million)
Exhibit 101 Prevalence Percentage of Erectile Dysfunction with Respect to Age in Spain
Exhibit 102 Erectile Dysfunction Treatment Market in Spain 2020–2026 ($ million)
Exhibit 103 Erectile Dysfunction Treatment Market in APAC 2020−2026 ($ million)
Exhibit 104 Incremental Growth in APAC 2020 & 2026
Exhibit 105 Erectile Dysfunction Treatment Market in Japan 2020–2026 ($ million)
Exhibit 106 Erectile Dysfunction Treatment Market in China 2020–2026 ($ million)
Exhibit 107 Erectile Dysfunction Treatment Market in India 2020–2026 ($ million)
Exhibit 108 Erectile Dysfunction Treatment Market in Australia 2020−2026 ($ million)
Exhibit 109 Erectile Dysfunction Treatment Market in South Korea 2020−2026 ($ million)
Exhibit 110 Erectile Dysfunction Treatment Market in Latin America 2020–2026 ($ million)
Exhibit 111 Incremental Growth in Latin America 2020 & 2026
Exhibit 112 Erectile Dysfunction Treatment Market in Brazil 2020–2026 ($ million)
Exhibit 113 Erectile Dysfunction Treatment Market in Mexico 2020−2026 ($ million)
Exhibit 114 Erectile Dysfunction Treatment Market in Argentina 2020–2026 ($ million)
Exhibit 115 Erectile Dysfunction Treatment Market in MEA 2020–2026 ($ million)
Exhibit 116 Incremental Growth in Middle East & Africa 2020 & 2026
Exhibit 117 Erectile Dysfunction Treatment Market in Saudi Arabia 2020–2026 ($ million)
Exhibit 118 Erectile Dysfunction Treatment Market in UAE 2020–2026 ($ million)
Exhibit 119 Erectile Dysfunction Treatment Market in South Africa 2020–2026 ($ million)
Exhibit 120 Key Vendors offering ED Devices
Exhibit 121 Eli Lilly and Company: Revenue Generated by Human Pharmaceutical Segment 2018 & 2019 ($ million)
Exhibit 122 Eli Lilly and Company Revenue Share by Region 2018 & 2019 ($ million)
Exhibit 123 Eli Lilly and Company R&D Investments 2017−2019 ($ million)
Exhibit 124 Eli Lilly and Company: Revenue for Cialis (tadalafil) in US 2017−2019 ($ million)
Exhibit 125 Vivus: Revenue Data 2017−2019 ($ million)
Exhibit 126 Vivus: R&D Investments from 2017−2019 ($ million)
Exhibit 127 Vivus: Revenue by Geographic Region 2019 (%)
Exhibit 128 Vivus: Revenue by Stendra/Spedra 2017−2019 ($ million)
Exhibit 129 Pfizer: R&D Investments 2017−2019 ($ million)
Exhibit 130 Pfizer: Revenue by Segment 2018 & 2019 ($ million)
Exhibit 131 Pfizer: Revenue by Geographical Regions 2019 (%)
Exhibit 132 Pfizer: Revenue by Viagra (Sildenafil citrate) 2017−2019 ($ million)
Exhibit 133 Bayer: Revenue 2017−2019 ($ million)
Exhibit 134 Bayer: R&D Investments 2017−2019 ($ million)
Exhibit 135 Bayer: Revenue by Segment 2018 & 2019 ($ million)
Exhibit 136 Bayer: Revenue by Geographic Regions 2019 (%)
Exhibit 137 Boston Scientific: Revenue in 2017−2019 ($ million)
Exhibit 138 Boston Scientific: R&D Expenses 2017−2019 ($ million)
Exhibit 139 Boston Scientific: Revenue by Segment 2018 & 2019 ($ million)
Exhibit 140 Boston Scientific: Revenue by Region in 2019 (%)
Exhibit 141 Coloplast: Revenue 2017−2019 ($ million)
Exhibit 142 Coloplast: R&D Investments 2017−2019 ($ million)
Exhibit 143 Coloplast: Revenue by Segments 2018 & 2019 ($ million)
Exhibit 144 Coloplast: Revenue by Region 2019 (%)
Exhibit 145 Teva Pharmaceuticals: Revenue 2017−2019 ($ million)
Exhibit 146 Teva Pharmaceuticals: R&D Investments 2017−2019 ($ million)
Exhibit 147 Teva Pharmaceuticals: Revenue by Regions in 2018 & 2019 (in million)
Exhibit 148 Viatris: Total Revenue 2017−2019 ($ million)
Exhibit 149 Viatris: Revenue by Region 2019 (%)
Exhibit 150 Dong- A-Socio Holdings: Revenue 2017−2019 ($ million)
Exhibit 151 Dong-A-Socio Holding: R&D Investments 2017−2019 ($ million)
List Of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2020
Table 3 Popular Definitions of Erectile Dysfunction
Table 4 Etiology of ED According to its Sub-type
Table 5 Investigational Drugs/Devices for the Treatment of Erectile Dysfunction
Table 6 Withdrawn/ Terminated Drug Candidates or Devices
Table 7 Comparison of Pharmacological Drugs for Treating ED
Table 8 Different Companies and their Products with Advanced & Innovative Technologies
Table 9 Key Strategic Agreements & Collaborations in Erectile Dysfunction Treatment Market
Table 10 Companies and their Products Offering Novel Erectile Dysfunction Drug Formulations
Table 11 Adverse Events & Limitations of Phosphodiesterase-5 (PDE-5) Inhibitors
Table 12 Efficacy and Safety Profile of Topical Alprostadil Cream for the Treatment of ED
Table 13 Different Companies and their Product Expiry Date
Table 14 Comparing the Activity of Popular PDE-5 Inhibitors
Table 15 Significant Vendors Offering PDE-5 Inhibitors for ED Treatment
Table 16 Significant Players Offering Penile Implants
Table 17 Significant Vendors Offering Vacuum Constriction Devices
Table 18 List of Companies Offering Low-intensity Shock Wave Therapy Products for ED
Table 19 Erectile Dysfunction Treatment Market in US by Product 2020−2026 ($ million)
Table 20 Erectile Dysfunction Treatment Market in Canada by Product 2020−2026 ($ million)
Table 21 Ratio Rates of Minimal, Moderate, and Complete ED with Medical Condition
Table 22 Erectile Dysfunction Treatment Market in UK by Product 2020−2026 ($ million)
Table 23 Erectile Dysfunction Treatment Market in Germany by Product 2020−2026 ($ million)
Table 24 Erectile Dysfunction Treatment Market in France by Product 2020−2026 ($ million)
Table 25 Erectile Dysfunction Treatment Market in Italy by Product 2020−2026 ($ million)
Table 26 Erectile Dysfunction Treatment Market in Spain by Product 2020−2026 ($ million)
Table 27 Erectile Dysfunction Treatment Market in Japan by Product 2020−2026 ($ million)
Table 28 Erectile Dysfunction Treatment Market in China by Product 2020−2026 ($ million)
Table 29 Erectile Dysfunction Treatment Market in India by Product 2020−2026 ($ million)
Table 30 Erectile Dysfunction Treatment Market in Australia by Product 2020−2026 ($ million)
Table 31 Erectile Dysfunction Treatment Market in South Korea by Product 2020−2026 ($ million)
Table 32 Erectile Dysfunction Treatment Market in Brazil by Product 2020−2026 ($ million)
Table 33 Erectile Dysfunction Treatment Market in Mexico by Product 2020−2026 ($ million)
Table 34 Erectile Dysfunction Treatment Market in Argentina by Product 2020−2026 ($ million)
Table 35 Erectile Dysfunction Treatment Market in Saudi Arabia by Product 2020−2026 ($ million)
Table 36 Erectile Dysfunction Treatment Market in UAE by Product 2020−2026 ($ million)
Table 37 Erectile Dysfunction Treatment Market in South Africa by Product 2020−2026 ($ million)
Table 38 Key Vendors in ED Drugs Market
Table 39 Other Prominent Vendors Offering ED Drugs
Table 40 Vendors Offering Various ED Devices
Table 41 Eli Lily and Company: Major Product Offerings
Table 42 Vivus: Major Product Offerings
Table 43 Pfizer: Major Product Offerings
Table 44 Bayer: Major Product Offerings
Table 45 Boston Scientific: Major Product Offerings
Table 46 Coloplast: Major Product Offerings
Table 47 Teva Pharmaceuticals: Major Product Offerings
Table 48 Viatris: Major Product Offerings
Table 49 Dong-A Socio Holdings: Major Product Offerings
Table 50 Aurobindo Pharma: Major Product Offerings
Table 51 Dr. Reddy’s Laboratories: Major Product Offerings
Table 52 Cristalia: Major Product Offerings
Table 53 Metuchen Pharmaceuticals: Major Product Offerings
Table 54 Menarini Group: Major Product Offerings
Table 55 SK Chemicals: Major Product Offerings
Table 56 Seelos Therapeutics: Major Product Offerings
Table 57 GlaxoSmithKline: Major Product Offerings
Table 58 Sanofi: Major Product Offerings
Table 59 Lupin: Major Product Offerings
Table 60 Cipla: Major Product Offerings
Table 61 Sandoz: Major Product Offerings
Table 62 Endo International: Major Product Offerings
Table 63 Ferring Pharmaceuticals: Major Product Offerings
Table 64 ADVANZ PHARMA: Major Product Offerings
Table 65 Alembic Pharmaceuticals: Major Product Offerings
Table 66 Guangzhou Pharmaceutical Holdings: Major Product Offerings
Table 67 iX Biopharma: Major Product Offerings
Table 68 Dornier MedTech: Major Product Offerings
Table 69 Zephyr Surgical Implants: Major Product Offerings
Table 70 Augusta Medical Systems: Major Product Offerings
Table 71 Launch Medical: Major Product Offerings
Table 72 Bonro Medical: Major Product Offerings
Table 73 Owen Mumford: Major Product Offerings
Table 74 Direx Group: Major Product Offerings
Table 75 Zimmer Medizin Systeme: Major Product Offerings
Table 76 MTS Medical UG: Major Product Offerings
Table 77 Medispec: Major Product Offerings
Table 78 Inceler Medical: Major Product Offerings
Table 79 NOVAmedtek: Major Product Offerings
Table 80 WIKKON: Major Product Offerings
Table 81 Top Quality Group: Major Product Offerings
Table 82 Promedon: Major Product Offerings
Table 83 Timm medical technologies: Major Product Offerings
Table 84 Global Life Technologies: Major Product Offerings
Table 85 Urology Health Store: Major Product Offerings
Table 86 Hims: Major Product Offerings
Table 87 Global Erectile Dysfunction Market by Product 2020−2026 ($ million)
Table 88 Global Erectile Dysfunction Market by Product 2020−2026 (%)
Table 89 Global Erectile Dysfunction Treatment Market by Geography 2020−2026 ($ million)
Table 90 Global Erectile Dysfunction Treatment Market by Geography 2020−2026 (%)
Table 91 North America Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)
Table 92 North America Erectile Dysfunction Treatment Market by Product 2020−2026 (%)
Table 93 Europe Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)
Table 94 Europe Erectile Dysfunction Treatment Market by Product 2020−2026 (%)
Table 95 APAC Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)
Table 96 APAC Erectile Dysfunction Treatment Market by Product 2020−2026 (%)
Table 97 Latin America Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)
Table 98 Latin America Erectile Dysfunction Treatment Market by Product 2020−2026 (%)
Table 99 Middle East & Africa Erectile Dysfunction Treatment Market by Product 2020−2026 ($ million)
Table 100 Middle East & Africa Erectile Dysfunction Treatment Market by 2020−2026 (%)
Table 101 Global Erectile Dysfunction Drugs Market by ROA 2020−2026 ($ million)
Table 102 Global Erectile Dysfunction Drugs Market by ROA 2020−2026 (%)
Table 103 Global Erectile Dysfunction Drugs Market by Distribution Channel 2020−2026 ($ million)
Table 104 Global Erectile Dysfunction Drugs Market by Distribution Channel 2020−2026 (%)
Table 105 Global Erectile Dysfunction Drugs Market by Geography 2020−2026 ($ million)
Table 106 Global Erectile Dysfunction Drugs Market by Geography 2020−2026 (%)
Table 107 Global Erectile Dysfunction Devices Market by Product 2020−2026 ($ million)
Table 108 Global Erectile Dysfunction Devices Market by Product 2020−2026 (%)
Table 109 Global Erectile Dysfunction Devices Market by Geography 2020−2026 ($ million)
Table 110 Global Erectile Dysfunction Devices Market by Geography 2020−2026 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
DAYS
HOURS
MINUTES
SECONDS
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
